Literature DB >> 20534686

Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort.

Mikio Sugimoto1, Taizo Shiraishi, Hiroyuki Tsunemori, Takayoshi Demura, Yuko Saito, Toshiyuki Kamoto, Yoshiyuki Kakehi.   

Abstract

OBJECTIVES: The present study was carried out to analyze pathological features of prostatectomy specimens performed at different timing and trigger during active surveillance.
METHODS: One hundred and thirty-four patients that fit a selection condition similar to the so-called Hopkins' criteria were enrolled into the present study between January 2002 and December 2003. Patients were recommended to start curable treatment when they showed prostate-specific antigen-doubling time of 2 years or shorter or pathological progression at 1-year re-biopsy. Median observation period was 61 months.
RESULTS: Fourteen patients underwent radical prostatectomy immediately after enrollment (Group A) whereas 28 patients underwent radical prostatectomy after substantial periods of active surveillance (Group B). Of the 28 Group B, trigger of radical prostatectomy was on protocol in 17 patients (Group B1) whereas 11 patients underwent radical prostatectomy by their preference (Group B2). Upgrade from initial biopsy was observed in 43% of Group A and 68% of Group B. Upgrade was more frequently observed in Group B1 than B2 with border line significance (P = 0.075). Perineural infiltration and positive surgical margin rates of Group B1 were significantly higher than those of B2 (P < 0.05).
CONCLUSIONS: Unfavorable pathological features of surgical specimens were more frequently observed in patients who underwent radical prostatectomy due to short prostate-specific antigen-doubling time or biopsy findings than those who underwent radical prostatectomy because of other reasons including patients' preference. Rates of unfavorable pathological features at radical prostatectomy that deviate initial selection criteria was high enough to support integration of frequent biopsies into active surveillance program.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534686     DOI: 10.1093/jjco/hyq082

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer.

Authors:  Katsuyoshi Hashine; Hiroyuki Iio; Yoshiteru Ueno; Shohei Tsukimori; Iku Ninomiya
Journal:  Int J Clin Oncol       Date:  2013-06-22       Impact factor: 3.402

Review 2.  Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes.

Authors:  Yoshiyuki Kakehi
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

3.  Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN.

Authors:  Mikio Sugimoto; Hiromi Hirama; Akito Yamaguchi; Hirofumi Koga; Katsuyoshi Hashine; Iku Ninomiya; Nobuo Shinohara; Satoru Maruyama; Shin Egawa; Hiroshi Sasaki; Yoshiyuki Kakehi
Journal:  World J Urol       Date:  2014-11-27       Impact factor: 4.226

4.  Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?

Authors:  Mikio Sugimoto; Yoshiyuki Kakehi
Journal:  Asian J Androl       Date:  2012-06-18       Impact factor: 3.285

5.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

6.  The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.

Authors:  Hiromi Hirama; Mikio Sugimoto; Kazuto Ito; Taizo Shiraishi; Yoshiyuki Kakehi
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-19       Impact factor: 4.553

Review 7.  Current status of active surveillance in prostate cancer.

Authors:  Mun Su Chung; Seung Hwan Lee
Journal:  Investig Clin Urol       Date:  2016-01-11

Review 8.  Prostate cancer in East Asia: evolving trend over the last decade.

Authors:  Yao Zhu; Hong-Kai Wang; Yuan-Yuan Qu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.